Sample Letter of Medical Necessity for Vitiligo Treatment

[Date]
[Insurer name]
Attn: [Name of individual]
[Address]

re: [Patient name]
[Policy number]

Dear [Insurer name]:

I am writing on behalf of [Patient name] to document the medical necessity of [insert treatment option here] for the treatment of vitiligo. This letter provides information about the patient’s medical history and diagnosis and a statement summarizing my treatment rationale.

Vitiligo, or the depigmentation of skin and hair, is a medical condition that can have a devastating effect on a patient's quality of life, causing physical discomfort, secondary skin problems, social/emotional sequelae such as anxiety and depression, and occupational and relationship challenges. This has certainly been true for [Patient name], who has been impacted by vitiligo for [insert duration of symptoms here].
Specifically, [he or she] has had difficulties with [insert quality-of-life, social/emotional and/or career/daily living problems here].

[Discuss patient’s diagnosis, treatment history, and degree of illness]

[Insert patient's name] has tried the aforementioned therapies thus far without success and I, therefore, recommend [insert treatment option here] as the next logical choice for treating [his or her] vitiligo.

In light of this clinical information, and this patient’s condition, [insert treatment option
here] is medically necessary and warrants coverage. Please contact me at [(000) 000-
0000] if you require additional information.

Sincerely,
[Physician’s name]

Enclosed: Vitiligo Research Documentation

Selected Vitiligo Research References

Elbuluk N, Ezzedine K. [Quality of Life, Burden of Disease, Co-morbidities, and Systemic Effects in Vitiligo Patients.](https://pubmed.ncbi.nlm.nih.gov/28317521/)*Dermatol Clin*. 2017;35(2):117-128. doi:10.1016/j.det.2016.11.002

Morales-Sánchez MA, Vargas-Salinas M, Peralta-Pedrero ML, Olguín-García MG, Jurado-Santa Cruz F. [Impact of Vitiligo on Quality of Life. Impacto del vitíligo en la calidad de vida.](https://pubmed.ncbi.nlm.nih.gov/28456327/) *Actas Dermosifiliogr*. 2017;108(7):637-642. doi:10.1016/j.ad.2017.03.007

Kota RS, Vora RV, Varma JR, Kota SK, Patel TM, Ganjiwale J. [Study on Assessment of Quality of Life and Depression in Patients of Vitiligo.](https://pubmed.ncbi.nlm.nih.gov/30984590/) *Indian Dermatol Online J*. 2019;10(2):153-157. doi:10.4103/idoj.IDOJ\_14\_18

Yucel D, Sener S, Turkmen D, Altunisik N, Sarac G, Cumurcu HB. [Evaluation of the Dermatological Life Quality Index, sexual dysfunction and other psychiatric diseases in patients diagnosed with vitiligo with and without genital involvement](https://pubmed.ncbi.nlm.nih.gov/33191544/) [published online ahead of print, 2020 Nov 15]. *Clin Exp Dermatol*. 2020;10.1111/ced.14511. doi:10.1111/ced.14511

Bae JM, Lee SC, Kim TH, et al. [Factors affecting quality of life in patients with vitiligo: a nationwide study.](https://pubmed.ncbi.nlm.nih.gov/28391642/) *Br J Dermatol*. 2018;178(1):238-244. doi:10.1111/bjd.15560

Nicolaidou E, Mastraftsi S, Tzanetakou V, Rigopoulos D. [Childhood Vitiligo.](https://pubmed.ncbi.nlm.nih.gov/30911977/) *Am J Clin Dermatol*. 2019;20(4):515-526. doi:10.1007/s40257-019-00430-0

Ezzedine K, Silverberg N. [A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children.](https://pubmed.ncbi.nlm.nih.gov/27328922/) *Pediatrics*. 2016;138(1):e20154126. doi:10.1542/peds.2015-4126